1. Learn how detection of low-level residual leukemic cells can help develop a better understanding of relapse risk and impact treatment strategies.
2. Evaluate the potential of the SureSeq Myeloid MRD Plus Panel for MRD analysis compared to traditional technologies, including its sensitivity for broad biomarker ranges and complex variants like FLT3-ITDs.
3. Understand how ultrahigh-sensitivity NGS panels can be integrated into genomic workflows to generate comprehensive genomic profiles from AML research samples.
SureSeq: For Research Use Only. Not for Use in Diagnostic Procedures.